Truist Financial Maintains Integra Lifesciences(IART.US) With Hold Rating, Cuts Target Price to $21
Integra Lifesciences Analyst Ratings
Truist Raises Price Target on Integra LifeSciences Holdings to $26 From $21, Keeps Hold Rating
B of A Securities Maintains Underperform on Integra Lifesciences, Lowers Price Target to $18
BTIG Upgrades Integra Lifesciences(IART.US) to Hold Rating, Maintains Target Price $20
Integra Lifesciences Sell Rating: Overly Ambitious Targets Amid Persistent Operational Challenges
Integra LifeSciences Is Maintained at Sell by Citigroup
Integra Lifesciences Analyst Ratings
Citi Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $16
Wells Fargo Downgrades Integra Lifesciences(IART.US) to Hold Rating, Cuts Target Price to $25
Integra Lifesciences: Hold Rating Amidst Compliance Challenges and Revenue Impact With a Long-Term Recovery Outlook
BTIG Maintains Integra Lifesciences(IART.US) With Sell Rating, Maintains Target Price $20
BTIG Sticks to Their Sell Rating for Integra Lifesciences (IART)
BTIG Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $20
Integra Lifesciences Analyst Ratings
Citi Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $20
Morgan Stanley Maintains Integra Lifesciences(IART.US) With Sell Rating, Cuts Target Price to $25
A Quick Look at Today's Ratings for Integra Lifesciences(IART.US), With a Forecast Between $22 to $35
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $26
Integra Lifesciences (IART) Receives a Sell From Morgan Stanley